Recruiting · registry statusLooking for skin markers of future Parkinson’s in people with tremor
Researchers examine a Parkinson’s-related protein in skin samples to study whether it helps identify people with essential tremor who later develop Parkinson’s.
Learning by observing or collecting information · Study reference: NCT07428447
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
Open the official registry record ↗Who can join?
Ages 50 years to 85 years · Does not accept healthy volunteers
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: all
Inclusion Criteria:
* Age 50-85 years old
* Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
* Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
* Willing to participate in all study procedures
* Able and willing to provide written informed consent
Exclusion Criteria:
* Under age 50, Over age 85
* Clinical evidence of severe peripheral vascular disease
* Clinically active coronary artery or cerebrovascular disease
* Participant is currently on anticoagulant or dual anti-platelet therapy
* Alcoholism
* Allergic reaction to local anesthesia
* History of or increased risk for impaired wound healing, scarring, or keloid formation
* Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
* History of other neurodegenerative disorder or evidence of neurological co-pathology
* Abnormal DaTscan
* Participant is currently receiving treatment with carbidopa-levodopa for PD
* Isolated focal tremors (head, voice)
* Task-specific tremor (e.g., primary writing tremor)
* Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
* Sudden onset and step-wise deterioration
* Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.
Full study name & original research details
Official study title
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Original description
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.
Primary Objectives
1. Identify which ET patients have P-SYN pathology indicative of prodromal PD
2. Predict which patients are most likely to phenoconvert to PD
Conditions reported: Essential Tremor, Movement Disorders; Essential Tremor; Essential Tremor-plus
- Study type
- Observational
- Interventions
- Not reported
- Phases
- Not reported
- Sponsor
- CND Life Sciences
- Start date reported by registry
- 2026-02-18 (actual)
Registry updated: 2026-09-18 · Status last verified by the registry submitter: 2026-08
Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
Jeannie Director of Clinical Research · 480-434-6446 · ClinicalResearch@cndlifesciences.com
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
CND Clinical Research Center
Scottsdale, Arizona, United States
RecruitingJeannie Director of Clinical Research · 480-434-6446 · ClinicalResearch@cndlifesciences.com
Padma Mahant, MD
Neurology One
Orlando, Florida, United States
RecruitingJinna Santiago, RN, CRC · 407-706-3060 · jsantiago@n1research.org
Victor Lameda, CRC · 407-706-3060 · vlameda@n1research.org
Ramon L Rodriguez, MD, FAAN
Norton Healthcare
Louisville, Kentucky, United States
RecruitingAndrea J Gambrell, RN, BSN, CCM · 502-446-8544 · andrea.gambrell@nortonhealthcare.org
Hannah Scully, RN · 502-588-0719 · hannah.scully@nortonhealthcare.org
Jason Crowell, MD
Justin Phillips, MD
Veracity Neurosciences LLC
Memphis, Tennessee, United States
RecruitingHannah Touliatos · 901-443-9170 · hannah@veracityneuroscience.com
Mark LeDoux, MD, PhD
The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.